Method of reducing type 2 diabetes in high risk patients
A method of reducing diabetes in patients who are at risk for developing diabetes comprising administering to such patients an effective amount of an angiotensin converting enzyme (ACE) inhibitor for a sufficient period of time to prevent the development of diabetes in such patients; a method of slowing or reversing the decline of β-cell function in an individual comprising administering to an individual an effective amount of an ACE inhibitor; a method of increasing islet blood flow in an individual comprising administering to an individual an effective amount of an ACE inhibitor; a method of increasing pancreatic β-cell perfusion in an individual comprising administering to an individual an effective amount of an ACE inhibitor and a method of lowering aldosterone secretion and renal potassium wasting in an individual by comprising administering to an individual an effective amount of an ACE inhibitor.
1 . A method of preventing the development of diabetes in a patient who is at risk for developing diabetes, said method comprising administering to a patient, who is at risk for developing diabetes, an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to prevent the development of diabetes in such patient.
2 . A method according to claim 1 , wherein the diabetes is Type 2 Diabetes.
3 . A method according to claim 1 , wherein the angiotensin converting enzyme inhibitor is ramipril.
4 . A method according to claim 2 , wherein the angiotensin converting enzyme inhibitor is ramipril.
5 . A method of preventing, slowing or reversing the decline of β-cell function in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to prevent the decline of β-cell function in such individual.
6 . A method according to claim 5 , wherein the angiotensin converting enzyme inhibitor is ramipril.
7 . A method of increasing islet blood flow in an individual comprising:
administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase islet blood flow in such individual.
8 . A method according to claim 7 , wherein the angiotensin converting enzyme inhibitor is ramipril.
9 . A method of increasing pancreatic β-cell perfusion in an individual comprising:
administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase pancreatic β-cell perfusion in such individual.
10 . A method according to claim 9 , wherein the angiotensin converting enzyme inhibitor is ramipril.
11 . A method of lowering aldosterone secretion and renal potassium wasting in an individual by comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to lower aldosterone secretion and renal potassium wasting in such individual.
12 - 23 . (Canceled)
24 . A method according to claim 11 , wherein the angiotensin converting enzyme inhibitor is ramipril.
25 . A method of reducing diabetes in a patient, said method comprising administering to a patient an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to reduce diabetes in such patient.
26 . A method according to claim 25 , wherein the diabetes is Type 2 Diabetes.
27 . A method according to claim 25 , wherein the angiotensin converting enzyme inhibitor is ramipril.
28 . A method according to claim 26 , wherein the angiotensin converting enzyme inhibitor is ramipril.